Providing due diligence for an Alzheimer’s treatment

Challenge Our client, a major pension fund, was considering an investment in a Phase III neuroscience company, which was developing a small molecule to provide symptomatic relief of Alzheimer’s...
Learn More

Preparing an expert review paper

Challenge A venture-backed biotech company developing a clinical stage asset for the treatment of early-stage cancer was populating a data room and preparing for negotiations with a major pharma...
Learn More

Regulatory affairs due diligence in EU

Challenge An established generics company looking to acquire the French rights of an existing product franchise needed to perform regulatory and clinical due diligence on the French dossier.
Learn More

Point of care diagnostics due diligence

Challenge A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.
Learn More

Development strategy and business support for an early-stage oncology company

Challenge After a seed investment, Evgen, a start-up biotech had built an IP portfolio in the field of glucosinolates, chemicals found in brassica vegetables, that are potent inducers of...
Learn More

Conducting IP due diligence

Challenge We have conducted multiple due diligence projects, below are three examples:
Learn More

Assessment of an AAV gene therapy for an ophthalmic indication

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.
Learn More

Neuroscience Due Diligence

Alzheimer's due diligence Our client, a major pension fund, was considering an investment opportunity in a Phase III neuroscience company. The company was developing a small molecule to provide...
Learn More

Supporting due diligence on regulatory affairs

Challenge: A clinical stage biopharmaceutical specialist needed support with its regulatory due diligence activities for products in the respiratory field.
Learn More

Opportunity analysis - blood products

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company.  Alacrita was commissioned to provide a...
Learn More

Clinical strategy, medical oversight and clinical due diligence

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...
Learn More

Due diligence on a diagnostics investment opportunity

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...
Learn More
Previous
1 ... 4 5 6 7 8
Next
Content not found

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.